LNSR Stock Analysis: Buy, Sell, or Hold?
LNSR - LENSAR, Inc. Common Stock
$5.37
-0.23 (-4.11%)
▼
5d:
-6.61%
30d:
-12.54%
90d:
+5.5%
HOLD
LOW Confidence
Analysis Updated: Jul 27, 2026 12:00 AM ET
Earnings: Aug 06, 2026
8d
Get Alerted When LNSR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LNSR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: LNSR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: LNSR is currently trading at $5.37, which is considered oversold relative to its 30-day fair value range of $5.61 to $6.05. From a valuation perspective, the stock is trading at a discount (Forward PE: -7.9) compared to its historical average (14.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LNSR is in a downtrend. The price is currently testing key support at $5.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.50 (+51.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LNSR is in a downtrend. The price is currently testing key support at $5.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.50 (+51.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.61 -
$6.05
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 51.8% below Wall St target ($8.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -6.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$5.61 -
$6.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.37
Resistance Level
$5.91
Current Trend
Downtrend
Technical data as of
Jul 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.89
Wall Street Target
$8.50
(+51.8%)
Revenue Growth (YoY)
-5.2%
Profit Margin
50.9%
PE vs Historical
-7.9 vs 14.6
CHEAP
Share & Embed Analysis
Last updated: July 28, 2026 3:34 AM ET
Data refreshes hourly during market hours. Next update: 4:34 AM
Data refreshes hourly during market hours. Next update: 4:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LNSR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$72 | 52 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$86 | 46 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 49 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 49 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$100 | 57 HOLD |
